The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 20, 2021

Filed:

Dec. 22, 2016
Applicant:

The Doshisha, Kyoto, JP;

Inventors:

Noriko Koizumi, Kyoto, JP;

Naoki Okumura, Kyoto, JP;

Assignee:

THE DOSHISHA, Kyoto, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4439 (2006.01); A61P 27/02 (2006.01); A61P 43/00 (2006.01); A61K 31/17 (2006.01); A61K 31/4412 (2006.01); A61K 31/4418 (2006.01); A61K 31/573 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4439 (2013.01); A61K 31/17 (2013.01); A61K 31/4412 (2013.01); A61K 31/4418 (2013.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); A61P 27/02 (2018.01); A61P 43/00 (2018.01);
Abstract

Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth factor-β (TGF-β) signals, mitochondrial abnormalities, and/or endoplasmic reticulum (ER) associated stress in corneal endothelial cells, using p38 MAP kinase inhibitors. The present invention provides a drug which includes p38 MAP kinase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-β signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy.


Find Patent Forward Citations

Loading…